



VETERINARY MEETING & EXPO

The SHOW OF SHOWS

Title Text

WONDERS! WOWS! WISDOM!

JANUARY 13-17 🌻 ORLANDO, FL & ONLINE

Presented By:

NAVCA
YOUR VETERINARY COMMUNITY



CBC In Cancer Patients: What's Worriying? What's Not?

And Why Should I Care?

Guillermo Couto, DVM, DACVIM (SAIM, Oncology)

coutovetconsultants@gmail.com

Conflict of Interest Disclosure:

Consultant, IDEXX Laboratories, Inc
Thanks to Dr. Rebekah Mack-Gertig

**Note to Reviewers : All images property of Guillermo Couto, Rebekah Mack/
Education and Learning, or sourced by IDEXX SBC,**

The information contained herein is intended to provide general guidance only. As with any diagnosis or treatment, you should use clinical discretion with each patient based on a complete evaluation of the patient, including history, physical presentation, and complete laboratory data. With respect to any drug therapy or monitoring program, you should refer to product inserts for a complete description of dosages, indications, interactions, and cautions. Diagnosis and treatment decisions are the ultimate responsibility of the primary care veterinarian.

CBC In Oncology


- Provides a diagnosis
- Suggests subclinical neoplasia
- Staging?
- Monitoring response to treatment
- Monitoring chemotherapy
- Common hematologic abnormalities

CBC In Oncology



- Provides a diagnosis
- Suggests subclinical neoplasia
- Staging? Monitoring response to Rx
- Monitoring chemotherapy

CBC In Oncology

- Provides a diagno



Simon-WBC Dot Plots



Drs. Kate Sycamore and Jason Couto

CBC In Oncology

- Provides a diagnosis
- Suggests subclinical neoplasia
- Staging? Monitoring response to Rx
- Monitoring chemotherapy
- Common hematologic abnormalities

CBC In Oncology

- Suggests subclinical neoplasia
 - Anemia/erythrocytosis
 - Leukopenia
 - Neutropenia
 - Leukocytosis
 - Neutrophilia, lymphocytosis, eosinophilia, monocytosis
 - Thrombocytopenia/thrombocytosis
 - Bi- or pancytopenia

CBC In Oncology

- Provides a diagnosis
- Suggests subclinical neoplasia
- Staging?
- Monitoring response to Rx
- Monitoring chemotherapy
- Common hematologic abnormalities

CBC In Oncology

- Staging
 - Pancytopenia lymphoma patient

CBC In Oncology

- Provides a diagnosis
- Suggests subclinical neoplasia
- Staging?
- Monitoring response to Rx
- Monitoring chemotherapy
- Common hematologic abnormalities

CBC In Oncology

- Monitoring response to Rx
 - resolution of cytopenia/-cytosis

CBC In Oncology

- Provides a diagnosis
- Suggests subclinical neoplasia
- Staging?
- Monitoring response to Rx
- Monitoring chemotherapy
- Common hematologic abnormalities

CBC In Oncology

- Monitoring chemotherapy
 - Neutropenia
 - Thrombocytopenia
 - Iron-deficiency anemia

CBC In Oncology
























- Monitoring chemotherapy
 - Neutrophil “cut-off” for chemotherapy
 - $2.5 \times 10^9/\text{L}???$
 - $1.0 \times 10^9/\text{L}???$
 - Let common sense prevail...

CBC In Oncology

- Monitoring chemotherapy
 - Thrombocytopenia
 - 50 X 10⁹/L???
 - Is it real???


CBC In Oncology

- "Chewy", 4, MC, Mixed breed dog
- On CHOP for multientric lymphoma
- Here for VINCRISTINE today


Test	Results	Reference Interval	LOW	NORMAL	HIGH	
ProCyle Dx (July 13, 2012 1:06 PM)					8/26/12 10:35 AM	
RBC	5.97 M μ L	5.65 - 8.87				6.47 M μ L
HCT	42.5 %	37.3 - 51.7				46.0 %
HGB	14.8 g/dL	13.1 - 20.5				16.1 g/dL
MCV	71.2 fL	61.6 - 73.6				71.1 fL
MCH	24.8 pg	21.2 - 25.9				24.9 pg
MCHC	34.8 g/dL	32.0 - 37.9				35.0 g/dL
RDW	14.2 %	13.6 - 21.7				15.3 %
%RETIC	0.2 %					0.3 %
RETIC	13.7 K μ L	10.0 - 110.0				19.4 K μ L
WBC	* 8.16 K μ L	5.05 - 16.78				9.17 K μ L
%NEU	* 50.8 %					75.4 %
%LYM	* 33.6 %					15.2 %
%MONO	* 12.9 %					8.5 %
%EOS	* 2.5 %					2.4 %
%BASO	* 0.2 %					0.5 %
NEU	* 4.14 K μ L	2.95 - 11.64				6.91 K μ L
LYM	* 2.74 K μ L	1.05 - 5.10				1.39 K μ L
MONO	* 1.05 K μ L	0.18 - 1.12				0.60 K μ L
EOS	* 0.20 K μ L	0.06 - 1.23				0.22 K μ L
BASO	* 0.02 K μ L	0.00 - 0.10				0.05 K μ L
PLT	* 281 K μ L	145 - 450	LOW			176 K μ L
MPV	— fL	8.7 - 13.2				10.9 fL
PDW	— fL	8.1 - 19.4				12.7 fL
PCT	— %	0.14 - 0.48				0.19 %

PLT Aggregates Detected

PLT	24 K/ μ L	148 - 464	LEVY	
MPV	fL	8.7 - 13.2		
PDW	fL	9.1 - 19.4		
PCT	%	0.14 - 0.46		
PLT Aggregates Detected				



■ RBC
 ■ RETICS
 ■ PLT
 ■ RBC Frags
 ■ WBC



■ NEU
 ■ LYM
 ■ MONO
 ■ EOS
 ■ BASO
 ■ URBC

CBC In Oncology

- “Chewy”, 4, MC, Mixed breed dog
- On CHOP for multientric lymphoma
- Here for VINCRISTINE today
- And he got it!

The moral of the story: All “thrombocytopenias” should have a blood smear or cytogram review

CBC In Oncology

- Provides a diagnosis
- Suggests subclinical neoplasia
- Staging?
- Monitoring response to Rx
- Monitoring chemotherapy
- Common hematologic abnormalities

CBC In Oncology

- Red blood cells
- White blood cells
- Platelets

CBC In Oncology

- Red blood cells
- Anemia
- Erythrocytosis

Anemia

Regenerative

“Macrocytic
Hypochromic”

Blood loss
Hemolysis

Semi-regenerative

Microcytic
Hypochromic
Retics

Lots of platelets

Iron deficiency

Non regenerative

Normocytic
Normochromic


ACD
CKD
BM
(Endocrine)

With impedance analyzers,
90% of regenerative anemias
are NOT macrocytic, hypochromic

Anemia Of Chronic Disease (ACD)

- Most common anemia in cancer patients
- Mild, normocytic, normochromic
- Chronic cytokine->hepcidin release
- Fe “hoarding” by macrophages in BM/decreased Fe absorption
- Clinically relevant?

ACD



Anemia

Regenerative

“Macrocytic
Hypochromic”

Blood loss
Hemolysis

Semi-regenerative

Microcytic
Hypochromic
Retics

Lots of platelets

Iron deficiency

Non regenerative

Normocytic
Normochromic

ACD
CKD
BM
(Endocrine)

Which ones are common in cancer patients?

Anemia

Regenerative

“Macrocytic
Hypochromic”

Blood loss
Hemolysis

Semi-regenerative

Microcytic
Hypochromic
Retics

Lots of platelets

Iron deficiency

Non regenerative

Normocytic
Normochromic

ACD
CKD
BM
(Endocrine)

A dog with HSA has...

Anemia

Regenerative

“Macrocytic
Hypochromic”

Blood loss
Hemolysis

Semi-regenerative

Microcytic
Hypochromic
Retics
Lots of platelets


Iron deficiency

Non regenerative

Normocytic
Normochromic

ACD
CKD
BM
(Endocrine)


A dog with an intestinal tumor has...



Jejunal GIST

Patient


RBC Run



■ RBC ■ RETICS ■ PLT ■ RBC Frags ■ WBC

Normal

RBC Run




■ RBC ■ RETICS ■ PLT ■ RBC Frags ■ WBC





Erythrocytosis

- Appropriate or inappropriate release of EPO
- Autonomous RBC proliferation (Polycythemia vera)



Erythrocytosis



- Renal masses
- Extrarenal compression (pheo)

Erythrocytosis

- Tumor EPO production:
 - Renal carcinomas
 - Nasal fibrosarcoma
 - Any other tumor



CBC in oncology

White blood cells

01

Neutrophils

Neutrophilia/neutropenia

02

Lymphocytes

Lymphocytosis

03

Eosinophils

Eosinophilia

04

Monocytes

Monocytosis



Neutrophils



Neutrophilia

- + Necrosis
- + Systemic inflammation
- + Tumor G-CSF/ GM-CSF production

Neutropenia

- + BM involvement
- + Immune-mediated
- + Chemotherapy

White blood cells



Lymphocytosis

- + Leukemia
- + (CLL vs ALL)
- + Lymphoma
- + Thymoma


Eosinophilia


- + Lymphoma
- + SCCs
- + Other CAs

Monocytosis


- + Lymphoma
- + Necrotic tumors
- + “Not monocytes”

Leukemias








Acute



Chronic





CLL/Indolent lymphoma

“Monster”

- + 3-year-old, MC, Husky cross
- + Owned by vet student
- + Hypersalivating and panting all night
- + PE: cranial abdominal organomegaly



“Monster”

Client: [REDACTED]

Patient Name: monster

Species: Canine

Breed:

Gender:

Weight: 0.0 lbs


Age:

Doctor:

Test	Results	Reference Interval	LOW	NORMAL	HIGH
ProCyte Dx (December 26, 2012 11:03 AM)					
RBC	5.13 M/ μ L	5.65 - 8.87	LOW		
HCT	33.9 %	37.3 - 61.7	LOW		
HGB	11.9 g/dL	13.1 - 20.5	LOW		
MCV	66.1 fL	61.6 - 73.5			
MCH	23.2 pg	21.2 - 25.9			
MCHC	35.1 g/dL	32.0 - 37.9			
RDW	15.1 %	13.6 - 21.7			
%RETIC	0.1 %				
RETIC	7.2 K/ μ L	10.0 - 110.0	LOW		


“Monster”

WBC	4.36 K/ μ L	5.05 - 16.76	LOW
%NEU	22.0 %		
%LYM	19.5 %		
%MONO	57.8 %		
%EOS	0.7 %		
%BASO	0.0 %		
NEU	0.96 K/ μ L	2.95 - 11.64	LOW
LYM	0.85 K/ μ L	1.05 - 5.10	LOW
MONO	2.52 K/ μ L	0.16 - 1.12	HIGH
EOS	0.03 K/ μ L	0.06 - 1.23	LOW
BASO	0.00 K/ μ L	0.00 - 0.10	
PLT	49 K/ μ L	148 - 484	LOW
MPV	11.3 fL	8.7 - 13.2	
PDW	17.2 fL	9.1 - 19.4	
PCT	0.06 %	0.14 - 0.46	LOW





“Monster”


“Monster”



Normal







Bone Marrow

AML

CBC in Oncology

Platelets/hemostasis

01

Thrombocytopenia

02


Thrombocytosis

03

Bleeding

04

Thrombosis



CBC in Oncology

Platelets

+ **Thrombocytopenia**

+ 1/3 cancer patients

+ Leukemias

+ Lymphoma

+ Myeloma

+ HSA

+ MH

All “thrombocytopenias”
should have a blood smear or cytogram review

CBC in Oncology

Platelets

+ **Thrombocytosis**


- + 1/3 dogs with thrombocytosis have cancer
- + 50% of dogs w/carcinoma
- + Essential thrombocythemia
- + Clinically relevant?



CBC in Oncology

Bi- or Pancytopenia

- +Leukemia
- +Lymphoma
- +Myeloma
- +MH (hemophagocytic)




Let The Dotplots Tell A Story

“Pudge”


13-year-old, MC, Shepherd mix with
multicentric lymphoma on CHOP

CBC: WBC Dot Plot-Refresher




Day 1

RBC Run



■ RBC ■ RETICS ■ PLT ■ RBC Frags ■ WBC


WBC Run




■ NEU ■ LYM ■ MONO ■ EOS ■ BASO ■ URBC

Day 8

RBC Run




WBC Run




Day 30

RBC Run




WBC Run




Day 31



RBC Run



WBC Run




Day 32




Day 38

RBC Run



■ RBC ■ RETICS ■ PLT ■ RBC Frags ■ WBC


WBC Run



■ NEU ■ LYM ■ MONO ■ EOS ■ BASO ■ URBC


Day 86

RBC Run



■ RBC ■ RETICS ■ PLT ■ RBC Frags ■ WBC


WBC Run



■ NEU ■ LYM ■ MONO ■ EOS ■ BASO ■ URBC


Day 150

RBC Run



■ RBC ■ RETICS ■ PLT ■ RBC Frags ■ WBC


WBC Run



■ NEU ■ LYM ■ MONO ■ EOS ■ BASO ■ URBC


Day 156

RBC Run




■ RBC ■ RETICS ■ PLT ■ RBC Frags ■ WBC

WBC Run



■ NEU ■ LYM ■ MONO ■ EOS ■ BASO ■ URBC

“Pudge”–Sequential WBC



Questions?








"Simon", 9, MC, DSH

- Referred for hepatic lipidosis

Thanks to Drs. Jason Couto and Kate Sycamore



Simon-CBC-RBCs

 	RBC	6.75	6.54 - 12.20 M/ μ L	
 	Haematocrit	29.5	30.3 - 52.3 %	
 	Haemoglobin	10.0	9.8 - 16.2 g/dL	
 	MCV	43.7	35.9 - 53.1 fL	
 	MCH	14.8	11.8 - 17.3 pg	
 	MCHC	33.9	28.1 - 35.8 g/dL	
 	RDW	20.8	15.0 - 27.0 %	
	% Reticulocyte	0.2	%	
 	Reticulocytes	10.1	3.0 - 50.0 K/ μ L	
 	Reticulocyte Haemoglobin	14.5	13.2 - 20.8 pg	

Simon-CBC-WBCs










WBC	32.48	2.87 - 17.02 K/ μ L	
% Neutrophils	*52.6	%	
% Lymphocytes	*17.2	%	
% Monocytes	*29.5	%	
% Eosinophils	0.5	%	
% Basophils	0.2	%	
Neutrophils	*17.08	2.30 - 10.29 K/ μ L	
Bands	Suspected	85% sensitivity and 95% specificity	
Lymphocytes	*5.60	0.92 - 6.88 K/ μ L	
Monocytes	*0.57	0.05 - 0.67 K/ μ L	
Eosinophils	0.17	0.17 - 1.57 K/ μ L	
Basophils	0.06	0.01 - 0.26 K/ μ L	

DDx For Monocytosis

- ▶ Chronic neutropenia
- ▶ Granulocyte colony-stimulating factor administration
- ▶ Increased endogenous or exogenous corticosteroids (especially in dogs)
- ▶ Inflammation (eg, infectious vs noninfectious, acute vs chronic)
- ▶ Monocytic or monoblastic leukemia (very rare)
- ▶ Necrosis and/or tissue destruction (eg, feline immune-mediated hemolytic anemia)
- ▶ Paraneoplastic syndromes (associated with poor prognosis)
 - ▶ Monocyte chemotactic protein; possible secretion of granulocyte colony-stimulating factor
 - ▶ Osteosarcoma
- ▶ Recovery from acute bone marrow injury
 - ▶ Secondary to administration of a chemotherapeutic agent
 - ▶ Secondary to parvovirus infection (rare)



























But, are they really monocytes?

Simon-CBC-Platelets

  Platelets	50	151 - 600 K/ μ L	
  MPV	19.4	11.4 - 21.6 fL	
  Plateletcrit	0.10	0.17 - 0.86 %	

Always evaluate blood smear and/or dot plots for platelet clumping!

Simon-CBC-Chemistry 1

 	Glucose	139	71 - 159 mg/dL	
 	Creatinine	1.2	0.8 - 2.4 mg/dL	
 	Urea	35	16 - 36 mg/dL	
	BUN: Creatinine Ratio	30	SDMA 40 µg/dL (0-14 µg/dL)	
 	Phosphorus	7.4	3.1 - 7.5 mg/dL	
 	Calcium	9.7	7.8 - 11.3 mg/dL	
 	Sodium	158	150 - 165 mmol/L	
 	Potassium	5.2	3.5 - 5.8 mmol/L	
	Na: K Ratio	30		
 	Chloride	122	112 - 129 mmol/L	

Simon-UA

	Collection	Cystocentesis	
■	Colour	Dark Yellow	
■	Clarity	Clear	
■	Specific Gravity	1.024	
■	pH	6.0	
■	Urine Protein	TR	
■	Glucose	neg	
■	Ketones	neg	
■	Blood / Haemoglobin	250	Ery/ μ L
■	Bilirubin	3	mg/dL
■	Urobilinogen	8	mg/dL

■	White Blood Cells	1 /HPF
■	Red Blood Cells	6 /HPF
■	Bacteria, Cocci	Suspect presence
■	Bacteria, Rods	None detected
■	Squamous Epithelial Cells	None detected
■	Non-Squamous Epithelial Cells	<1 /HPF
■	Hyaline Casts	None detected
■	Non-Hyaline Casts	None detected
■	Calcium Oxalate Dihydrate Crystals	None detected
■	Struvite Crystals	None detected
■	Ammonium Biurate Crystals	None detected
■	Bilirubin Crystals	None detected
■	Unclassified Crystals	<1 /HPF

Are There Non-Renal Causes Of High SDMA?

- Yep...
- Greyhounds (RI: 0–20µg/dL)
 - <https://www.idexx.com/files/diagnostic-update-greyhound-specific-reference-intervals.pdf>
- Lymphoma and lymphoid leukemias


Received: 13 January 2022

Revised: 15 June 2022

Accepted: 15 June 2022

DOI: 10.1111/vco.12845

ORIGINAL ARTICLE



WILEY

The association between symmetric dimethylarginine concentrations and various neoplasms in dogs and cats

Michael J. Coyne  | **Corie Drake** | **Donald J. McCrann** | **David Kincaid**




1803 dogs and cats with neoplasia

TABLE 1 Median SDMA and Cr concentrations by tumour type

Tumour type	SDMA $\mu\text{mol/L}$ (range)		<i>p</i> value	Cr $\mu\text{mol/L}$ (range)		<i>p</i> value
	Case animals	Control animals		Case animals	Control animals	
Canine hemangiosarcoma	0.54 (0.1–1.53)	0.49 (0.2–2.97)	.136	79.6 (17.7–265.2)	79.6 (26.5–875.2)	.105
Canine lipoma	0.44 (0.1–1.24)	0.49 (0.15–2.03)	.004	79.6 (26.5–229.8)	79.6 (26.5–415.5)	.099
Canine lymphoma	3-98.8 $\mu\text{g/dL}$	0.49 (0.15–2.47)	<.0001	79.6 (17.7–406.6)	79.6 (35.4–919.4)	.897
Canine mammary adenocarcinoma	0.44 (0.1–1.33)	0.49 (0.1–2.82)	.006	61.9 (26.5–327.1)	70.7 (26.5–724.9)	<.0001
Canine mammary carcinoma	0.44 (0.1–2.22)	0.49 (0.05–4.94)	.008	61.9 (26.5–229.8)	79.6 (17.7–574.6)	<.0001
Feline lymphoma	2-98.8 $\mu\text{g/dL}$	0.54 (0.15–3.46)	<.0001	114.9 (44.2–1007.8)	123.8 (53.0–795.6)	<.0001
Feline visceral mast cell tumour	0.64 (0.25–1.93)	0.54 (0.25–4.35)	.566	132.6 (53.0–716.1)	132.6 (44.2–539.3)	.826



Cancer type	<i>N</i>	OR (95% CI)	<i>p</i>
Canine lymphoma	307	10.00 (5.98–16.72)	<i>p</i> < .001
Feline lymphoma	224	3.04 (1.95–4.73)	<i>p</i> < .001
Feline visceral mast cell tumour	55	1.63 (0.67–3.92)	<i>p</i> = .275
Canine hemangiosarcoma	230	1.11 (0.66–1.87)	<i>p</i> = .691
Canine mammary carcinoma	387	0.49 (0.28–0.84)	<i>p</i> = .009
Canine mammary adenocarcinoma	388	0.41 (0.231–0.71)	<i>p</i> = .001
Canine lipoma	212	0.39 (0.18–0.85)	<i>p</i> = .013

Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma



Shelby L. Sloan^{1,2}, Kyle A. Renaldo³, Mackenzie Long^{1,2}, Ji-Hyun Chung², Lindsay E. Courtney³, Konstantin Shilo⁴, Youssef Youssef², Sarah Schlotter², Fiona Brown², Brett G. Klamer⁵, Xiaoli Zhang⁵, Ayse S. Yilmaz⁵, Hatice G. Ozer⁵, Victor E. Valli^{6†}, Kris Vaddi⁷, Peggy Scherle⁷, Lapo Alinari², William C. Kisseberth^{2,3‡*}, Robert A. Baiocchi^{2‡*}


- 42.4% of lymphomas positive for PRMT5
- PRMT5 inhibition  Cell death


Simon-RBC Dot Plots





Simon-WBC Dot Plots













Simon-WBC Dot Plots



“Simon”

- Owners elected not to treat him